129 related articles for article (PubMed ID: 36007753)
1. Biopharmaceutical R&D outsourcing: Short-term gain for long-term pain?
Billette de Villemeur E; Scannell JW; Versaevel B
Drug Discov Today; 2022 Nov; 27(11):103333. PubMed ID: 36007753
[TBL] [Abstract][Full Text] [Related]
2. One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry.
Billette de Villemeur E; Versaevel B
J Health Econ; 2019 May; 65():260-283. PubMed ID: 31158785
[TBL] [Abstract][Full Text] [Related]
3. Schrödinger's pipeline and the outsourcing of pharmaceutical innovation.
McMeekin P; Lendrem DW; Lendrem BC; Pratt AG; Peck R; Isaacs JD; Jones D
Drug Discov Today; 2020 Mar; 25(3):480-484. PubMed ID: 31835019
[TBL] [Abstract][Full Text] [Related]
4. Economic Efficiency of Outsourcing Business Models: A Comparative Assessment.
Kulembayeva F; Seitkaziyeva A; Yelshibayev R
Glob J Flex Syst Manag; 2022; 23(1):75-88. PubMed ID: 38624730
[TBL] [Abstract][Full Text] [Related]
5. Economic viability of Stratified Medicine concepts: An investor perspective on drivers and conditions that favour using Stratified Medicine approaches in a cost-contained healthcare environment.
Fugel HJ; Nuijten M; Postma M
N Biotechnol; 2016 Dec; 33(6):860-867. PubMed ID: 27664792
[TBL] [Abstract][Full Text] [Related]
6. Scale, scope, and spillovers: the determinants of research productivity in drug discovery.
Henderson R; Cockburn I
Rand J Econ; 1996; 27(1):32-59. PubMed ID: 10160535
[TBL] [Abstract][Full Text] [Related]
7. Should We Pay for Scientific Knowledge Spillovers? The Underappreciated Value of "Failed" R&D Efforts.
Xie RZ; Towse A; Garrison LP
Int J Technol Assess Health Care; 2022 Mar; 38(1):e31. PubMed ID: 35297363
[TBL] [Abstract][Full Text] [Related]
8. Market power in the United States red meatpacking industry.
Koontz SR
Vet Clin North Am Food Anim Pract; 2003 Jul; 19(2):519-44. PubMed ID: 12951745
[TBL] [Abstract][Full Text] [Related]
9. Outsourcing and benchmarking in a rural public hospital: does economic theory provide the complete answer?
Young SH
Rural Remote Health; 2003; 3(1):124. PubMed ID: 15877485
[TBL] [Abstract][Full Text] [Related]
10. License Compliance Issues For Biopharmaceuticals: Special Challenges For Negotiations Between Companies And Non-Profit Research Institutions.
Ponzio TA; Feindt H; Ferguson S
LES Nouv; 2011 Sep; 46(3):216-225. PubMed ID: 22162900
[TBL] [Abstract][Full Text] [Related]
11. Social Non-profit Bioentrepreneurship: Current Status and Future Impact on Global Health.
Sadeghi AH; Koldeweij C; Trujillo-de Santiago G; Tannazi M; Hosseinnia N; van Loosbroek O; Manbachi A; Taverne YJHJ; Bogers AJJC; Alvarez MM
Front Public Health; 2021; 9():541191. PubMed ID: 34660499
[TBL] [Abstract][Full Text] [Related]
12. Guidelines, editors, pharma and the biological paradigm shift.
Singh AR; Singh SA
Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616
[TBL] [Abstract][Full Text] [Related]
13. The Minderoo-Monaco Commission on Plastics and Human Health.
Landrigan PJ; Raps H; Cropper M; Bald C; Brunner M; Canonizado EM; Charles D; Chiles TC; Donohue MJ; Enck J; Fenichel P; Fleming LE; Ferrier-Pages C; Fordham R; Gozt A; Griffin C; Hahn ME; Haryanto B; Hixson R; Ianelli H; James BD; Kumar P; Laborde A; Law KL; Martin K; Mu J; Mulders Y; Mustapha A; Niu J; Pahl S; Park Y; Pedrotti ML; Pitt JA; Ruchirawat M; Seewoo BJ; Spring M; Stegeman JJ; Suk W; Symeonides C; Takada H; Thompson RC; Vicini A; Wang Z; Whitman E; Wirth D; Wolff M; Yousuf AK; Dunlop S
Ann Glob Health; 2023; 89(1):23. PubMed ID: 36969097
[TBL] [Abstract][Full Text] [Related]
14. Outsourcing and children's social care: A longitudinal analysis of inspection outcomes among English children's homes and local authorities.
Bach-Mortensen AM; Goodair B; Barlow J
Soc Sci Med; 2022 Nov; 313():115323. PubMed ID: 36201866
[TBL] [Abstract][Full Text] [Related]
15. Sustainable rare diseases business and drug access: no time for misconceptions.
Rollet P; Lemoine A; Dunoyer M
Orphanet J Rare Dis; 2013 Jul; 8():109. PubMed ID: 23879976
[TBL] [Abstract][Full Text] [Related]
16. Incentives and disincentives to drug innovation: evidence from recent literature.
Lee Mendoza R
J Med Econ; 2019 Aug; 22(8):713-721. PubMed ID: 31038374
[No Abstract] [Full Text] [Related]
17. Beware the Medical-Industrial Complex.
Stevens CW; Glatstein E
Oncologist; 1996; 1(4):IV-V. PubMed ID: 10388005
[TBL] [Abstract][Full Text] [Related]
18. Unlocking the potential of established products: toward new incentives rewarding innovation in Europe.
Nayroles G; Frybourg S; Gabriel S; Kornfeld Å; Antoñanzas-Villar F; Espín J; Jommi C; Martini N; de Pouvourville G; Tolley K; Wasem J; Toumi M
J Mark Access Health Policy; 2017; 5(1):1298190. PubMed ID: 28740616
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
